CoChat
Sign Up
Cited by 336

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications

Brown, Brian D., Naldini, Luigi·2009·Nature Reviews Genetics
DOI 10.1038/nrg2628
Open this paper in CoChat — free account

Abstract

New technologies are emerging that utilize artificial microRNA (miRNA) target sites to exploit or inhibit endogenous miRNA regulation. This approach has been used to improve cell-specific targeting for gene and stem cell therapy studies and for animal transgenics, and also to reduce the toxicity of oncolytic viruses and to attenuate viral vaccines. Artificial targets have also been used to sponge or decoy miRNAs as a way to study their functions. This article considers the benefits of this approach and design considerations for future studies.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrg2628

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 8 references

Research works printed but not linked: 59

  1. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009). · DOI · Paper page
  2. Griffiths-Jones, S., Saini, H. K., van Dongen, S. & Enright, A. J. miRBase: tools for microRNA genomics. Nucleic Acids Res. 36, D154–D158 (2008). · DOI
  3. Brown, B. D. et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nature Biotechnol. 25, 1457–1467 (2007). · DOI
  4. Barnes, D., Kunitomi, M., Vignuzzi, M., Saksela, K. & Andino, R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4, 239–248 (2008). · DOI
  5. Kelly, E. J., Hadac, E. M., Greiner, S. & Russell, S. J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nature Med. 14, 1278–1283 (2008). · DOI
  6. Papapetrou, E. P., Kovalovsky, D., Beloeil, L., Sant'angelo, D. & Sadelain, M. Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. J. Clin. Invest. 119, 157–168 (2008).
  7. Edge, R. E. et al. A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol. Ther. 16, 1437–1443 (2008). · DOI
  8. Suzuki, T. et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol. Ther. 16, 1719–1726 (2008). · DOI
  9. Ylosmaki, E. et al. Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific microRNA. J. Virol. 82, 11009–11015 (2008). · DOI
  10. Cawood, R. et al. Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog. 5, e1000440 (2009). · DOI
  11. Mansfield, J. H. et al. MicroRNA-responsive 'sensor' transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression. Nature Genet. 36, 1079–1083 (2004). · DOI
  12. Brown, B. D. et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 110, 4144–4152 (2007). · DOI · Paper page
  13. Care, A. et al. MicroRNA-133 controls cardiac hypertrophy. Nature Med. 13, 613–618 (2007). · DOI
  14. Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature Methods 4, 721–726 (2007). · DOI · Paper page
  15. Scherr, M. et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 35, e149 (2007). · DOI
  16. Bonci, D. et al. The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Med. 14, 1271–1277 (2008). · DOI
  17. Gentner, B. et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nature Methods 6, 63–66 (2009). · DOI
  18. Kumar, M. S. et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. USA 105, 3903–3908 (2008). · DOI
  19. Valastyan, S. et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032–1046 (2009). · DOI
  20. Kelly, E. J. & Russell, S. J. MicroRNAs and the regulation of vector tropism. Mol. Ther. 17, 409–416 (2008). · DOI · Paper page
  21. Waehler, R., Russell, S. J. & Curiel, D. T. Engineering targeted viral vectors for gene therapy. Nature Rev. Genet. 8, 573–587 (2007). · DOI
  22. Schmidt-Supprian, M. & Rajewsky, K. Vagaries of conditional gene targeting. Nature Immunol. 8, 665–668 (2007). · DOI
  23. De Palma, M. et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105, 2307–2315 (2005). · DOI
  24. Brown, B. D. & Lillicrap, D. Dangerous liaisons: the role of 'danger' signals in the immune response to gene therapy. Blood 100, 1133–1140 (2002). · DOI
  25. Cao, O., Furlan-Freguia, C., Arruda, V. R. & Herzog, R. W. Emerging role of regulatory T cells in gene transfer. Curr. Gene Ther. 7, 381–390 (2007). · DOI
  26. Wolff, L. J., Wolff, J. A. & Sebestyen, M. G. Effect of tissue-specific promoters and microRNA recognition elements on stability of transgene expression after hydrodynamic naked plasmid DNA delivery. Hum. Gene Ther. 20, 374–388 (2009). · DOI
  27. Neilson, J. R., Zheng, G. X., Burge, C. B. & Sharp, P. A. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev. 21, 578–589 (2007). · DOI
  28. Colin, A. et al. Engineered lentiviral vector targeting astrocytes in vivo. Glia 57, 667–679 (2009). · DOI · Paper page
  29. Perez, J. T. et al. MicroRNA-mediated species-specific attenuation of influenza A virus. Nature Biotechnol. 27, 572–576 (2009). · DOI
  30. Haasnoot, J., Westerhout, E. M. & Berkhout, B. RNA interference against viruses: strike and counterstrike. Nature Biotechnol. 25, 1435–1443 (2007). · DOI
  31. Boden, D., Pusch, O., Lee, F., Tucker, L. & Ramratnam, B. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77, 11531–11535 (2003). · DOI
  32. Gitlin, L., Karelsky, S. & Andino, R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418, 430–434 (2002). · DOI
  33. Gitlin, L., Stone, J. K. & Andino, R. Poliovirus escape from RNA interference: short interfering RNA–target recognition and implications for therapeutic approaches. J. Virol. 79, 1027–1035 (2005). · DOI
  34. Vignuzzi, M., Wendt, E. & Andino, R. Engineering attenuated virus vaccines by controlling replication fidelity. Nature Med. 14, 154–161 (2008). · DOI
  35. Arai, F. et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149–161 (2004). · DOI
  36. De Palma, M., Venneri, M. A., Roca, C. & Naldini, L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nature Med. 9, 789–795 (2003). · DOI
  37. Constien, R. et al. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30, 36–44 (2001). · DOI
  38. Pucci, F. et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes (TEMs), blood 'resident' monocytes and embryonic macrophages suggests common functions and developmental relationships. Blood 21 Apr 2009 (doi:10.1182/blood-2009-01-200931). · DOI
  39. Doench, J. G., Petersen, C. P. & Sharp, P. A. siRNAs can function as miRNAs. Genes Dev. 17, 438–442 (2003). · DOI
  40. Kim, V. N., Han, J. & Siomi, M. C. Biogenesis of small RNAs in animals. Nature Rev. Mol. Cell Biol. 10, 126–139 (2009). · DOI · Paper page
  41. Horwich, M. D. & Zamore, P. D. Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells. Nature Protoc. 3, 1537–1549 (2008). · DOI
  42. Kloosterman, W. P. & Plasterk, R. H. The diverse functions of microRNAs in animal development and disease. Dev. Cell 11, 441–450 (2006). · DOI · Paper page
  43. Johnnidis, J. B. et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451, 1125–1129 (2008). · DOI · Paper page
  44. Chen, C. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005). · DOI
  45. Landthaler, M. et al. Molecular characterization of human Argonaute-containing ribonucleoprotein complexes and their bound target mRNAs. RNA 14, 2580–2596 (2008). · DOI
  46. Schmitter, D. et al. Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cells. Nucleic Acids Res. 34, 4801–4815 (2006). · DOI
  47. Xiao, C. et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131, 146–159 (2007). · DOI
  48. Grimson, A. et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91–105 (2007). · DOI · Paper page
  49. Doench, J. G. & Sharp, P. A. Specificity of microRNA target selection in translational repression. Genes Dev. 18, 504–511 (2004). · DOI
  50. Seitz, H. Redefining microRNA targets. Curr. Biol. 19, 870–873 (2009). · DOI
  51. Forstemann, K., Horwich, M. D., Wee, L., Tomari, Y. & Zamore, P. D. Drosophila microRNAs are sorted into functionally distinct argonaute complexes after production by dicer-1. Cell 130, 287–297 (2007). · DOI
  52. Brennecke, J., Stark, A., Russell, R. B. & Cohen, S. M. Principles of microRNA–target recognition. PLoS Biol. 3, e85 (2005). · DOI
  53. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437–1441 (2004). · DOI · Paper page
  54. Hutvagner, G. & Zamore, P. D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056–2060 (2002). · DOI · Paper page
  55. Filipowicz, W., Bhattacharyya, S. N. & Sonenberg, N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Rev. Genet. 9, 102–114 (2008). · DOI
  56. Behm-Ansmant, I. et al. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev. 20, 1885–1898 (2006). · DOI
  57. Ameres, S. L., Martinez, J. & Schroeder, R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130, 101–112 (2007). · DOI
  58. Zhao, Y., Samal, E. & Srivastava, D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436, 214–220 (2005). · DOI
  59. Kedde, M. et al. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell 131, 1273–1286 (2007). · DOI

Cited by

Sorted by citations

Metadata

Authors
Brown, B. D., & Naldini, L.
Venue
Nature Reviews Genetics
Publisher
Springer Science and Business Media LLC
Published
2009-08
Volume
10
Issue
8
Pages
578-585
ISSN
  • 1471-0056
  • 1471-0064
DOI
10.1038/nrg2628
Cited by
336
References
8
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review